Breaking News, Collaborations & Alliances

PharmaMar, Megapharm Partner for Multiple Myeloma

The commercialization and distribution license agreement is for Aplidin (plitidepsin)

PharmaMar is entering a commercialization and distribution license agreement with Megapharm for the marine-derived anticancer drug Aplidin (plitidepsin) in Israel and the territory known as the Palestinian Authority.   The drug is for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.    Under the agreement, Megapharm will register Aplidin on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters